Actuate Therapeutics files S-1/A
- Filed on 2026-10-14
- 65,000,000 shares of common stock offered
- Public offering price assumed at $0.6437 per share
ACTU
ACTUATE THERAPEUTICS, INC. SEC filings
Every EDGAR filing for ACTUATE THERAPEUTICS, INC. (ACTU), newest first, with AI summaries and stories.
- Ticker
- ACTU
- CIK
- 1652935
- Latest filing
- 5d
Next: 10-Q expected ~Nov 16 (deadline Nov 16)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINES-1/AACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINEFWPACTUATE THERAPEUTICS, INC.ACTULIVE Actuate Therapeutics files FWP
- Filed FWP on 2026-10-08
- Konik Capital is underwriter
- Bios Fund III Entities own 5,389,922 shares
NOTABLES-1ACTUATE THERAPEUTICS, INC.ACTULIVE Actuate Therapeutics files S-1
- 50,000,000 shares of common stock offered
- Public offering price assumed at $0.819 per share
- Underwriter has 45-day option to purchase additional 7,500,000 shares
ROUTINE4ACTUATE THERAPEUTICS, INC.ACTULIVE Daniel M Schmitt, insider filing for ACTU
Daniel M Schmitt, reporting
NOTABLE10-QACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINEDRSACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE4ACTUATE THERAPEUTICS, INC.ACTULIVE 7 insider filings
Dan Zabrowski, insider filing for ACTU
Show all 7
- 4Insider filing for ACTU
- 4Insider filing for ACTU
- 4Insider filing for ACTU
- 4Insider filing for ACTU
- 4Insider filing for ACTU
- 4Insider filing for ACTU
- 4Insider filing for ACTU
Dan Zabrowski, reporting
ROUTINES-8ACTUATE THERAPEUTICS, INC.ACTULIVE NOTABLE10-QACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE3ACTUATE THERAPEUTICS, INC.ACTULIVE Martin H. Huber Jr., new insider at ACTU
Martin H. Huber Jr., reporting
ROUTINEDEFA14AACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINESCHEDULE 13G/AACTUATE THERAPEUTICS, INC.ACTULIVE Ownership stake disclosure by Voss Capital, LP (amended)
Voss Capital, LP, filed by
ROUTINEARSACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINEDEFA14AACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINEDEF 14AACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE4ACTUATE THERAPEUTICS, INC.ACTULIVE 3 insider filings
Andrew Paul Mazar, insider filing for ACTU
Show all 3
- 4Insider filing for ACTU
- 4Insider filing for ACTU
- 4Insider filing for ACTU
Andrew Paul Mazar, reporting
NOTABLE10-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE4ACTUATE THERAPEUTICS, INC.ACTULIVE Daniel M Schmitt, insider filing for ACTU
Daniel M Schmitt, reporting
ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE4ACTUATE THERAPEUTICS, INC.ACTULIVE Todd S Thomson, insider filing for ACTU
Todd S Thomson, reporting ยท Kairos Venture Partners II, L.P., reporting
ROUTINESCHEDULE 13GACTUATE THERAPEUTICS, INC.ACTULIVE Ownership stake disclosure by Voss Capital, LP
Voss Capital, LP, filed by
ROUTINE144ACTUATE THERAPEUTICS, INC.ACTULIVE Kairos Venture Partners II, L.P., planned sale of ACTU shares
Kairos Venture Partners II, L.P., reporting
ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE424B5ACTUATE THERAPEUTICS, INC.ACTULIVE ROUTINE8-KACTUATE THERAPEUTICS, INC.ACTULIVE ACTUATE THERAPEUTICS, INC. reported: Other Information.
- Item 8.01 Other Information.
NOTABLE10-QACTUATE THERAPEUTICS, INC.ACTULIVE Actuate Therapeutics, Inc. (ACTU) filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational progress.